159748-56-8

Upstream product

• 2042-37-7 o-cyanobromobenzene 
• 269410-24-4 5-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 
• 10075-50-0 5-bromo-1H-indole 

Downstream Products

• 159749-07-2 5-(2-cyanophenyl)-1-[1-(4-trifluoromethylphenyl)-1-pentyl]indole 
• 159748-17-1 5-[2-(2H-tetrazol-5-yl)phenyl]-1-[1-(4-trifluoromethylphenyl)-1-pentyl]indole 
• 159748-98-8 methyl 3-[5-(2-cyanophenyl)indol-1-yl]nonanoate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors

The crystal structure of viral infectivity factor (Vif) was reported recently, which makes it possible to design new inhibitors against Vif by structure-based drug design. Through analysis of the protein surface of Vif, the C2 pocket located in the N-terminal was found, which is suit for developing small molecular inhibitors. Then, in our article, fragment-based virtual screening (FBVS) was conducted and a series of fragments was obtained, among which, Zif-1 bearing indole scaffold and pyridine ring can form H-bonds with Tyr148 and Ile155. Subsequently, 19 derivatives of Zif-1 were synthesized. Through the immune-fluorescence staining and Western blot assays, Zif-15 shows potent activity in inhibiting Vif-mediated A3G degradation. Further docking experiment shows that Zif-15 form H-bond interactions with residues His139, Tyr148 and Ile155. Therefore, Zif-15 is a promising lead compound against Vif that can be used to treat AIDS.

Angiotensin II antagonists

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist intermediates

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.